Notre Dame licensee Hsiri Therapeutics enters into agreement for the treatment of mycobacterial diseases

Author: Nick Swisher

Hsiri Therapeutics Logo

University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).

Marvin MillerMarvin Miller

It is reported that the number of patients suffering from NTM diseases has been increasing especially in developed countries, in recent years. There is a medical need to develop novel anti-NTM drugs because of long-term regimen and insufficient treatment outcome of current therapeutics. TB is one of the three major infectious diseases in the world, and new cases of TB are estimated 10.4 million/year. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) have become a major public health concern, and novel drugs for MDR-TB and XDR-TB are anticipated.The candidate compounds discovered by Hsiri have a novel mechanism of action and are hence anticipated to be more effective than current therapies for mycobacterial infections. These compounds had their origins in the lab of Marvin J. Miller, the George and Winifred Clark Professor of Chemistry and Biochemistry Emeritus at Notre Dame. Shionogi’s strength in small molecule drug discovery and development in the antibacterial area will support development of Hsiri’s innovative therapeutics in this collaborative program. Under the terms of this agreement, Shionogi will have exclusive right to develop, manufacture, and commercialize the compounds worldwide. Hsiri will receive an upfront license fee, potential development milestones, and royalty payments based on sales from Shionogi.

Shionogi’s research and development targets infectious disease as one of its priority areas, and Shionogi have positioned “protecting people from the threat of infectious diseases” as one of its social mission targets. Through this cooperation, Shionogi strives constantly to bring forth innovative drugs for the treatment of infectious diseases, to protect the health of patients we serve.

About Hsiri Therapeutics, Inc.
Hsiri Therapeutics, Inc. is a pre-clinical stage company specializing in novel antimicrobials. Hsiri was founded by two University of Notre Dame graduates and is based on technology and assets licensed from the University of Notre Dame. Hsiri’s business model is to acquire discovery phase compounds by license and internal research and to develop them to pharmacologic proof of concept. Hsiri’s portfolio includes novel compounds for the treatment of mycobacterial diseases, drug resistant gram-negative bacterial infections, and drug-resistant anaerobic bacterial infections. For further information, please visit

Originally published by Nick Swisher at on June 14, 2018.